Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication

• Published in: Hematological oncology Vol. 26; no. 3; pp. 139 - 147
• Main Authors: Ghesquières, Hervé, Ferlay, Céline, Sebban, Catherine, Chassagne, Catherine, Carausu, Liana, Gargi, Thérèse, Favier, Bertrand, Philip, Irène, Blay, Jean-Yves, Biron, Pierre
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01-09-2008
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; chemotherapy; daily practice; diffuse large B-cell lymphoma; Female; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Rituximab
• ISSN: 0278-0232; 1099-1069
• DOI: 10.1002/hon.850

Randomized trials have demonstrated improved outcome from adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for patients with diffuse large B‐cell lymphoma (DLBCL). This retrospective study compared the outcomes of 224 patients with DLBCL treated in our institution before (Period 1, 1996–2002) and after (Period 2, 2002–2005) approval of rituximab in this indication to evaluate the impact of the drug in daily practice in unselected patients receiving different types of chemotherapy. We treated 131 patients in Period 1 versus 93 in Period 2 (median follow‐up, 75 and 29 months, respectively) with no difference in patient characteristics between the two periods. Event‐free and overall survivals (EFS and OS) were significantly improved in Period 2 for elderly patients and a significant shift in the selection of regimens was observed at the time when rituximab became available. More patients received the CHOP regimen in Period 2 than in Period 1 (82 vs. 57%, p < 0.007) with CHOP being substituted for epirubicin‐based regimens. In younger patients treated mostly with the ACVBP regimen (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) these differences were not observed, suggesting that combination of rituximab with dose‐dense chemotherapy may deserve further evaluation in this age group. Copyright © 2008 John Wiley & Sons, Ltd.